Singapore markets closed
Straits Times Index
3,322.62 +14.72 (+0.45%) S&P 500
5,307.01 -14.40 (-0.27%) Dow
39,671.04 -201.95 (-0.51%) Nasdaq
16,801.54 -31.08 (-0.18%) Bitcoin USD
69,920.96 -125.30 (-0.18%) CMC Crypto 200
1,506.67 +4.01 (+0.27%)
Hikma Pharmaceuticals PLC (H5P.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 09:14AM CEST. Market open.
| Previous close | 22.80 |
| Open | 22.80 |
| Bid | 23.00 x N/A |
| Ask | 23.40 x N/A |
| Day's range | 22.80 - 22.80 |
| 52-week range | 19.70 - 25.60 |
| Volume | |
| Avg. volume | 1 |
| Market cap | 5.059B |
| Beta (5Y monthly) | 0.44 |
| PE ratio (TTM) | 29.23 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.67 (2.94%) |
| Ex-dividend date | 21 Mar 2024 |
| 1y target est | N/A |
- Simply Wall St.
With 52% institutional ownership, Hikma Pharmaceuticals PLC (LON:HIK) is a favorite amongst the big guns
Key Insights Significantly high institutional ownership implies Hikma Pharmaceuticals' stock price is sensitive to...
- Simply Wall St.
Optimism around Hikma Pharmaceuticals (LON:HIK) delivering new earnings growth may be shrinking as stock declines 3.3% this past week
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
- Reuters
Merck's Bridion faces generic threat from drugmaker Hikma
Merck has received a letter that Hikma Pharmaceuticals US unit has sought a pre-patent expiry approval from the US FDA to sell a generic version of its Bridion injection, the drugmaker said in filing on Monday. Merck said, on Feb. 5, it received the letter under the Hatch-Waxman Act, through which a company can seek FDA approval to market a copycat before the expiration of patents related to the brand-name drug. Merck said in the filing that it is currently considering its options.
© 2024 Yahoo. All rights reserved.